（1-（2-氯苯基）环丁基）甲胺盐酸盐 | 1228879-40-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: （1-（2-氯苯基）环丁基）甲胺盐酸盐
• 英文名称: 1-(2-chlorophenyl)cyclobutane-1-amine hydrochloride
• 英文别名: 1-(2-chlorophenyl)cyclobutan-1-amine hydrochloride；1-(2-chlorophenyl)cyclobutan-1-amine;hydrochloride
• CAS: 1228879-40-0
• 化学式: C₁₀H₁₂ClN*ClH
• 分子量: 218.126
• InChiKey: KKBTUTICMYPLQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  2-氯嘧啶-5-羧酸乙酯 、 （1-（2-氯苯基）环丁基）甲胺盐酸盐 在 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 以68.4%的产率得到ethyl 2-((1-(2-chlorophenyl)cyclobutyl)amino)pyrimidine-5-carboxylate
  参考文献：
  名称：

  KR2017/43091

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(o-Chlorophenyl)-cyclobutancarboxamid 在 sodium hypochlorite 、 sodium hydroxide 、 盐酸 作用下， 以 叔丁醇 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 12.0h， 以63.7%的产率得到（1-（2-氯苯基）环丁基）甲胺盐酸盐
  参考文献：
  名称：

  KR2017/43091

  摘要：

  公开号：

文献信息

• [EN] MAP4K1 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K1
  申请人：BAYER AG

  公开号：WO2022167627A1

  公开（公告）日：2022-08-11

  The present invention relates to Map4K1 inhibitors of formula (I) (I), wherein A, E, G, Q, R1, R2and R4have the same meaning as defined in the description, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及公式（I）（I）的Map4K1抑制剂，其中A，E，G，Q，R1，R2和R4的含义与说明中定义的相同，涉及包含根据本发明的化合物的制药组合物和组合物，以及创新化合物的预防和治疗用途，分别用于制造用于治疗或预防疾病的制药组合物，特别是用于肿瘤性疾病，或与异常MAP4K1信号相关的其他紊乱免疫反应或其他疾病，作为唯一药物或与其他活性成分联合使用。本发明还涉及用于制造用于治疗或预防良性增生，动脉粥样硬化疾病，败血症，自身免疫性疾病，血管疾病，病毒感染，神经退行性疾病，炎症性疾病，动脉粥样硬化疾病和男性生育控制的制药组合物的使用，分别使用上述化合物制造制药组合物。
• OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Chong Kun Dang Pharmaceutical Corp.

  公开号：EP3362445A1

  公开（公告）日：2018-08-22
• [EN] OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS D'OXADIAZOLE AMINE UTILISÉS EN TANT QU'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2017065473A1

  公开（公告）日：2017-04-20

  The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.
• KR2017/43091
  申请人：——

  公开号：——

  公开（公告）日：——